【单选题】{{B}}Text 2{{/B}}
If such pills catch on, they could generate significant revenues for drug companies. In Pfizer’s ease, the goal is to transfer as many qualified patients as possible to the combo pill. Norvasc’s patents expire in 2007, but Pfizer could avoid losing all its revenues from the drug at once if it were part of a superpill. Sena Lund, an analyst atCathay Financial, sees Pfizer selling $4.2 billion worth of Norvasc-Lipitor by 2007. That would help take up the slack for falling sales of Lipitor, which he projects will drop to $5 billion in 2007, down from $ 8 billion last year.
Pfizer argues that addressing two distinct and serious cardiovascular risk factors in one pill has advantages. People with both hypertension and high LDL cholesterol (the "bad" kind) number around 27 million in the U. S. , notesCraig Hopkinson, medical director for dual therapy at Pfizer, and only 2% of that population reaches adequate treatment goals. Taking two treatments in one will increase the number of patients who take the medications properly and "assist in getting patients to goal," be says.
Doctors also may be quick to adopt Norvasc-Lipitor, Pfizer figures, because it’s made up of two well-studied drugs, which many physicians are already familiar with.ButDr. Stanley Rockson, chief of consultative cardiology at Stanford University MedicalCenter, says fixed-dose combination pills represent "an interesting crossroads" for physicians, who are typically trained to "approach each individual problem with care."Combining treatments would challenge doctors to approach heart disease differently.But better patient compliance is important enough, says Rockson, that he expects doctors, toBe open to trying the combined pill.
Some other physicians are more skeptical. "If you want to change dosage on one of the new pill’s two drugs, you’re stuck," fearsDr. Irene Gavris, professor of medicine atBoston University School of Medicine. She says she would feel most comfortable trying the combination pill on patients who "have been on the drugs for a while" and are thus unlikely to need changes in dosage.
As usual, economics could tip the scales. Patients now taking both Lipitor and Norvasc "could cut their insurance co pay in half" by switching to the combo drug, Gavris notes. That’s a key advantage.Controlling hypertension, for instance, can require three or more drugs, and the financial burden on patients mounts quickly. If patients also benefit--as Pfizer and other drug companies contend--making the switch to superpills could be advantageous for everyone.
B．explain Pfizer’s expectation of doctors’ support
C．illustrate doctors’ possible reception of combopills
D．stress the importance of patient compliance
网考网参考答案：C
网考网解析：
[解析] 本题涉及段落的写作意图。第三段讲述了病人对超级药丸的接受态度，第四段主要讲述医生们可能的接受态度，所以答案为C。A项不对，因为本段内部并没有进行对比。 document.getElementById("warp").style.display="none"; document.getElementById("content").style.display="block"; 查看试题解析出处>>
发布评论 查看全部评论